The Board of Directors of Vimta Labs have approved, company's foray into Biologics Contract Research and Development activities (CDMO), subject to Shareholder's approval.

The industry or area to which the new line of business belongs to is Biologics Contract Research and Development.

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides that will strengthen our service portfolio to biopharmaceutical industry, enabling acceleration of our business growth.

The estimated amount to be invested in the new business is Rs. 50 crores.